The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
U.S. FDA grants orphan drug designation for PTG-300 for the treatment of polycythemia vera
PTG-300, an injectable hepcidin mimetic peptide, has received orphan drug designation by the U.S. Food and Drug Administration on June 12, 20201.
Polycythemia vera (PV) is a type of myeloproliferative neoplasm, causing elevated levels of red blood cells which may lead to thrombotic events. Hematocrit levels maintained below 45% may help reducing the risk of thrombotic events.
PTG-300 provides a non-cytoreductive mechanism to control hematocrit levels, thereby managing symptoms and improving systemic iron deficiency in patients with PV2. It is currently being developed for the treatment of PV and hereditary hemochromatosis and initial phase II results showed a well-tolerated safety profile, as well as a robust clinical response and clinically meaningful dose-related control of hematocrit levels at individual patient-level2.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content